Antibody · 고형암 (전체)

249개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved249 programs
AntibodyLimited DatastaleGenelux CorporationPhase 2

Platinum-doublet with or without bevacizumab (Platinum-doublet with or without bevacizumab)

Ovarian Cancer; Peritoneal Carcinomatosis · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#monoclonal-antibody#PeritonealCarcinomatosis+1
Trials 1Status Active
AntibodyLimited DatastaleAIO-Studien-gGmbHPhase 2

trastuzumab (Herceptin, Post-operative treatment trastuzumab mono therapy)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#monoclonal-antibody#AdenocarcinomaoftheStomach+1
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 1

RAD001, Cetuximab, Irinotecan (RAD001, Cetuximab, Irinotecan)

Colorectal Cancer; Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#monoclonal-antibody#ColorectalCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleRegeneronPhase 2

REGN15505+Cemiplimab (REGN15505+Cemiplimab)

Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) · Metastatic Castration-Resistant Prostate

#MetastaticCastration-ResistantPr#Antibody#Phase2#monoclonal-antibody#ClearCellRenalCellCarcinomaccRCC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Associazione
Trials 1Status Active
AntibodyLimited DatastaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#monoclonal-antibody#Eli
Trials 1Status Active
AntibodyLimited DatastaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#monoclonal-antibody#UrethralCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#monoclonal-antibody#Carcinoma+3
Trials 1Status Active
AntibodyLimited DatastaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#monoclonal-antibody#StageIVSquamousCellLungCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleAbramson Cancer Center at Penn …Phase 1

atezolizumab (Tecentriq, SBRT + atezolizumab and bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase1#monoclonal-antibody#Abramson
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Centre, Singapo…Phase 2

atezolizumab (Tecentriq, SIRT-Y90 with Atezolizumab + Bevacizumab)

Locally Advanced Hepatocellular Carcinoma · Locally Advanced Hepatocellular Carcinom

#LocallyAdvancedHepatocellularCar#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Recruiting
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleInnoventPhase 2

Sintilimab and Bevacizumab Combined with Radiotherapy (Sintilimab and Bevacizumab Combined with Radiotherapy)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

Sintilimab combined with Bevacizumab (Sintilimab combined with Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Preclinical#monoclonal-antibody#Innovent
Trials 1Status Active
AntibodyLimited DatastaleInnoventPreclinical

pembrolizumab (Keytruda, MPA, Sintilimab or Pembrolizumab and medroxyprogesterone acetate, Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA))

Endometrial Cancer; Endometrioid Carcinoma · Endometrial Cancer

#EndometrialCancer#Antibody#Preclinical#monoclonal-antibody#EndometrioidCarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 1

TACE combined with sintilimab and bevacizumab (TACE combined with sintilimab and bevacizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital of G…Phase 2

TACE combined with sorafenib and tislelizumab (TACE combined with sorafenib and tislelizumab)

Hepatocellular Carcinoma Non-resectable · Hepatocellular Carcinoma Non-resectable

#HepatocellularCarcinomaNon-resec#Antibody#Phase2#monoclonal-antibody#Second
Trials 1Status Active

10 / 13 pages

← PreviousNext →